The invention relates to a novel method for producing a stable precipitate enriched in phycobiliproteins by means of salicylic acid precipitation. The invention also relates to the use of said precipitate enriched in phycobiliproteins for producing cosmetic or dermatological, and food or nutraceutical compositions.

Disclosed is a method to prepare a myceliated high-protein food product, which includes culturing a fungi an aqueous media which has a high level of protein, for example at least 20 g protein per 100 g dry weight with excipients, on a dry weight basis. The fungi can include Pleurotus ostreatus, Pleurotus eryngii, Lepista nuda, Hericium erinaceus, Lentinula edodes, Agaricus blazeii, Laetiporus sulfureus and combinations thereof. After culturing, the material is harvested by obtaining the myceliated high-protein food product via drying or concentrating. The resultant myceliated high-protein food product may have its taste, flavor, or aroma modulated, such as by increasing desirable flavors or tastes such as meaty, savory, umami, popcorn and/or by decreasing undesirable flavors such as bitterness, astringency or beaniness. Deflavoring and/or deodorizing as compared to non-myceliated control materials can also be observed. Also disclosed are myceliated high-protein food products.

The present invention relates to a pharmaceutical composition and a health functional food composition for preventing, alleviating or treating inflammatory diseases, including Toxoplasma gondii GRA9 protein or a gene encoding the protein as an active ingredient. The present inventors have identified the C-terminal region essential for the NLRP3-mediated mechanism of action and function of Toxoplasma gondii GRA9 in macrophages, which are host immune cells and confirmed the substantial anti-inflammatory and antibacterial effects and the antiseptic effect in vivo. Accordingly, Toxoplasma gondii GRA9 protein or a gene encoding the protein is expected to be usefully utilized in the field of prevention or treatment of inflammatory diseases caused by an abnormal NLRP3-mediated inflammatory response, including sepsis.

The present invention relates to a pharmaceutical composition and a health functional food composition for preventing, alleviating or treating inflammatory diseases, including Toxoplasma gondii GRA9 protein or a gene encoding the protein as an active ingredient. The present inventors have identified the C-terminal region essential for the NLRP3-mediated mechanism of action and function of Toxoplasma gondii GRA9 in macrophages, which are host immune cells and confirmed the substantial anti-inflammatory and antibacterial effects and the antiseptic effect in vivo. Accordingly, Toxoplasma gondii GRA9 protein or a gene encoding the protein is expected to be usefully utilized in the field of prevention or treatment of inflammatory diseases caused by an abnormal NLRP3-mediated inflammatory response, including sepsis.

Provided herein are compositions comprising a biocompatible microsphere, a biofilm-generating probiotic bacterium, a prebiotic, and/or a prebiofilmic. Methods for preparing and formulating the compositions and methods for treating or preventing a disease using the compositions are also provided.

Provided herein are compositions comprising a biocompatible microsphere, a biofilm-generating probiotic bacterium, a prebiotic, and/or a prebiofilmic. Methods for preparing and formulating the compositions and methods for treating or preventing a disease using the compositions are also provided.

Provided are purification methods and uses of a recombinant mutant collagenase, and methods for preparing high-purity mutant ColH and the purified enzyme product. The method for preparing high-purity mutant ColH includes expressing recombinant mutant collagenase protein with single mutation of E451D in ColH by using specific host strain E. coli BL21 (DE3), and improving yield of the target protein after induction by low-temperature fermentation. The purification includes five steps: Capto Phenyl HS hydrophobic interaction chromatography; Capto Q anion exchange chromatography; Capto Octyl hydrophobic interaction chromatography; Phenyl HP hydrophobic interaction chromatography and Source 15Q anion exchange chromatography. The target protein obtained has purity of over 98%.

Provided are purification methods and uses of a recombinant mutant collagenase, and methods for preparing high-purity mutant ColH and the purified enzyme product. The method for preparing high-purity mutant ColH includes expressing recombinant mutant collagenase protein with single mutation of E451D in ColH by using specific host strain E. coli BL21 (DE3), and improving yield of the target protein after induction by low-temperature fermentation. The purification includes five steps: Capto Phenyl HS hydrophobic interaction chromatography; Capto Q anion exchange chromatography; Capto Octyl hydrophobic interaction chromatography; Phenyl HP hydrophobic interaction chromatography and Source 15Q anion exchange chromatography. The target protein obtained has purity of over 98%.

Food products are provided in which microbial protein sources, such as single cell protein or protein hydrolysis products, are incorporated. Artificial meat products are provided that include microbial protein in place of animal protein.

Food products are provided in which microbial protein sources, such as single cell protein or protein hydrolysis products, are incorporated. Artificial meat products are provided that include microbial protein in place of animal protein.